What do systematic reviews say?

Non‐serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.

Adverse events during treatment period · people with newly diagnosed epilepsy

Adverse events during treatment period · people with newly diagnosed epilepsy

Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

Number of participants experiencing muscle‐related adverse events: e.g. soreness, discomfort, cramps, pain · men with urinary incontinence following prostate surgery

Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life

Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life

Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

Adverse outcome: unintended adverse events attributable to the intervention ATCS Plus, IVR versus usual care · patients with diabetes mellitus

Adverse events (such as cardiovascular events, respiratory events or illness resulting from immune deficiency) · critically ill adult patients

Adverse events (such as cardiovascular events, respiratory events or illness resulting from immune deficiency) · critically ill adult patients

Adverse events (such as cardiovascular events, respiratory events or illness resulting from immune deficiency) · critically ill adult patients

Adverse outcome: unintended adverse events attributable to the intervention ATCS Plus, IVR versus various controls · participants addicted to alcohol

Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs

Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs

Proportion of participants with adverse events with a probable causal link with the study interventions at six months · adults undergoing cataract surgery with IOL implantation

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged less than 11 years

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 5 to 49 years